Seeking Alpha

In a landmark decision, India's Supreme Court rejects Novartis' (NVS) bid for patent protection...

In a landmark decision, India's Supreme Court rejects Novartis' (NVS) bid for patent protection for its cancer drug Glivec, thus allowing the country's generic drugmakers to continue to sell copies at a lower price. Novartis India fell 1.8% on the Bombay exchange while generic manufacturer Natco Pharma surged 5.4%.
Comments (2)
  • jimc174
    , contributor
    Comments (2) | Send Message
     
    Not surprise here. India has a long history of not respecting intellectual property rights, and is the co leader with China in making counterfeit products. Historically, countries which do not respect intellectual property rights have very little of their own. The loss of investment in India because of the country's stance on intellectual property is considerable.
    1 Apr 2013, 10:50 AM Reply Like
  • Rage1979
    , contributor
    Comments (22) | Send Message
     
    Clearly you do not understand the patent case. It is based on a polymorph, which is a secondary and/or tertiary level of protection. This patent has been denied or revoked in many countries globally. This is a prime example of big pharma spin on a story which is a classic case of a government denying the game of ever-greening. There was little to no innovation on this "polymorph" and therefore should not be entitled to patent protection. US, EU, and other developed countries invalidate these types of patents 50% or more when brought through the Court system. This is not your standard "Big pharma's innovation is not be protected" case; innovation ws not present. This is a classic denial of ever-greening and keeping molecules off generic for a period longer than the granted monopoly. Greed in action.... understand the underlying IP case before you make a "patently" false statement
    1 Apr 2013, 12:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|